Compositions and methods of treating cancer with glycomimetic peptides
AssigneeSusavion Biosciences, Inc.
InventorsLaura L. Eggink, J. Kenneth Hoober
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to pharmaceutical compositions comprising a peptide or multivalent polypeptide, and an anti-cancer agent. In some embodiments, the anti-cancer agent is conjugated to the peptide or multivalent polypeptide. The present disclosure also relates to a method of treating cancer or reducing cancer cell proliferation using the peptide or multivalent polypeptide. In some aspects, the peptide or multivalent polypeptide enhances the efficacy of the anti-cancer agent, the targeting of the anti-cancer agent to the cancer cells, or both.
Claims20
A pharmaceutical composition, comprising:
- a pharmaceutically acceptable carrier;
- an anti-cancer agent;
- and
- a therapeutic peptide, wherein the therapeutic peptide comprises:
- a sequence of X1-X2-X3-X4-X5-X6-X7-X8, or
- a construct having a central framework, a linker sequence, and at least two arms,
- wherein each arm consists of a core sequence of X1-X2-X3-X4-X5-X6-X7-X8,
- and each arm is linked to the central framework via the linker sequence,
- wherein
- X1 is H or N,
- X2 is P or Q,
- X3 is S or H,
- X4 is H, T, or L,
- X5 is P or K,
- X6 is R, L, or S,
- X7 is S, or L, and
- X8 is G, and
- wherein the therapeutic peptide and the anti-cancer agent are conjugated by a chemical conjugation or an enzymatic conjugation.
A method of reducing cancer cell proliferation, comprising contacting the cancer cell with a pharmaceutical composition in an amount sufficient to reduce cancer cell proliferation, the pharmaceutical composition comprising:
- a pharmaceutically acceptable carrier;
- an anti-cancer agent;
- and
- a therapeutic peptide, wherein the therapeutic peptide comprises:
- a sequence of X1-X2-X3-X4-X5-X6-X7-X8, or
- a construct having a central framework, a linker sequence, and at least two arms,
- wherein each arm consists of a core sequence of X1-X2-X3-X4-X5-X6-X7-X8,
- and each arm is linked to the central framework via the linker sequence,
- wherein
- X1 is H or N,
- X2 is P or Q,
- X3 is S or H,
- X4 is H, T, or L,
- X5 is P or K,
- X6 is R, L, or S,
- X7 is S, or L, and
- X8 is G,
- wherein the pharmaceutical composition further comprises a second therapeutic peptide, and
- wherein
- the anti-cancer agent comprises cyclic dinucleotide (CDN),
- the second therapeutic peptide comprises a construct having a central framework,
- a linker sequence, and four arms, each arm consisting of a core sequence of NQHTPR (SEQ ID NO:
- 1) and is linked to the central framework via the linker sequence, and
- the second therapeutic peptide and CDN are conjugated via a linker.
A method of treating cancer in a subject in need thereof, comprising administering to the subject in an amount sufficient to slow cancer progression in the subject,
- an anti-cancer agent;
- and
- a therapeutic peptide, wherein the therapeutic peptide comprises:
- a sequence of X1-X2-X3-X4-X5-X6-X7-X8, or
- a construct having a central framework, a linker sequence, and at least two arms,
- wherein each arm consists of a core sequence of X1-X2-X3-X4-X5-X6-X7-X8,
- and each arm is linked to the central framework via the linker sequence,
- wherein
- X1 is H or N,
- X2 is P or Q,
- X3 is S or H,
- X4 is H, T, or L,
- X5 is P or K,
- X6 is R, L, or S,
- X7 is S, or L, and
- X8 is G, and
- wherein the administration of the anti-cancer agent precedes the administration of the therapeutic peptide by at least 1 day.
Dependencies are inferred from the claim text.